Comments
The stock of Bafna Pharmaceuticals jumped 5.77 per cent at ₹33 on the BSE after Crisil upgraded its short-term and long-term ratings in respect of total bank facilities. The rating agency has upgraded the rating to Crisil BB-/stable (from Crisil D) for the long term and Crisil A4+ (from Crisil D) for the short term. Instruments with this rating are considered to have minimal degree of safety regarding timely payment of financial obligations.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.